Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial K(ATP) channel

Simvastatin, a cholesterol-lowering agent, can protect against endothelial dysfunction. However, the effects of simvastatin treatment on the restoration of blood flow to ischemic myocardium are not known. This study sought to assess such effects of simvastatin on an experimental model of myocardial...

Full description

Saved in:
Bibliographic Details
Published in:British journal of pharmacology 2006-10, Vol.149 (3), p.243-249
Main Authors: Zhao, J-L, Yang, Y-J, Cui, C-J, You, S-J, Gao, R-L
Format: Article
Language:English
Subjects:
Animals
Antigens, CD - blood
Cadherins - blood
Cholesterol - blood
Coronary Circulation - drug effects
Female
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
Male
Myocardial Infarction - drug therapy
Myocardial Infarction - physiopathology
Potassium Channels - drug effects
Simvastatin - pharmacology
Swine
Swine, Miniature
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Simvastatin, a cholesterol-lowering agent, can protect against endothelial dysfunction. However, the effects of simvastatin treatment on the restoration of blood flow to ischemic myocardium are not known. This study sought to assess such effects of simvastatin on an experimental model of myocardial no-reflow and to explore possible mechanisms. Coronary ligation area and area of no-reflow were determined by myocardial contrast echocardiography in vivo and by histology in mini-pigs randomized into 7 study groups: controls, pretreated with simvastatin for 2 days, treated with 5-hydroxydecanoate (5-HD, the selective mitochondrial K(ATP) channel blocker), treated with simvastatin+5-HD, treated with HMR 1883 (the selective sarcolemmal K(ATP) channel blocker), treated with simvastatin+HMR 1883 and a sham-operated group. The myocardial no-reflow model was induced with 3 h occlusion of the left anterior descending coronary artery followed by 2 h reperfusion. Compared with the control group, simvastatin significantly increased coronary blood flow, decreased the area of no-reflow assessed echocardiographically and reduced the necrotic area, by histology. There was no significant difference in these outcomes between simvastatin and simvastatin+HMR 1883 groups. In contrast, 5-HD abolished the effect of simvastatin. Simvastatin can reduce the area and myocardial no-reflow after ischaemia and reperfusion. This beneficial effect is due to its activation of mitochondrial K(ATP) channels.
ISSN:0007-1188